EB 101 - Abeona Therapeutics

Drug Profile

EB 101 - Abeona Therapeutics

Alternative Names: Epidermolysis bullosa gene therapy - Abeona therapeutics; Gene-corrected skin grafts - Abeona Therapeutics; LEAES; LZRSE COL7A1; LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

Latest Information Update: 31 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University
  • Developer Abeona Therapeutics; Epidermolysis Bullosa Research Partnership; Stanford University
  • Class Gene therapies; Skin disorder therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epidermolysis bullosa

Most Recent Events

  • 29 Jan 2018 The US FDA grants the Regenerative Medicine Advanced Therapy designation for recessive dystrophic Epidermolysis bullosa
  • 29 Jan 2018 Abeona Therapeutics completes a phase I/II trial for Epidermolysis bullosa (In adolescents, In adults) in USA
  • 29 Aug 2017 EB 101 - Abeona Therapeutics receives Breakthrough Therapy status for Epidermolysis bullosa in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top